We are live on
!
Find out more
MCM
Manchester Capital Management Portfolio holdings
AUM
$694M
1-Year Est. Return
22.34%
This Fund
S&P 500
This Quarter
Est. Return
+10.95%
1 Year Est. Return
+22.34%
3 Year Est. Return
+57.67%
5 Year Est. Return
+66.95%
10 Year Est. Return
+238.55%
AUM
$764M
AUM Growth
+$33.5M
(+4.6%)
Cap. Flow
-$43M
Cap. Flow
% of AUM
-5.62%
Top 10 Holdings %
Top 10 Hldgs %
53.52%
Holding
1,145
New
99
Increased
305
Reduced
260
Closed
119
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Health Care ETF
VHT
|
+$23.8M |
| 2 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$10.2M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$8.2M |
| 4 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$7.64M |
| 5 |
T. Rowe Price
TROW
|
+$2.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$35.3M |
| 2 |
Tesla
TSLA
|
+$25M |
| 3 |
ENJY
Enjoy Technology, Inc. Common Stock
ENJY
|
+$6.68M |
| 4 |
Shopify
SHOP
|
+$4.86M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 20% |
| 2 | Technology | 10.2% |
| 3 | Financials | 8.19% |
| 4 | Healthcare | 5.44% |
| 5 | Consumer Discretionary | 4.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
Zoetis
ZTS
$30.9B
| $22K | ﹤0.01% |
92
-1,111
| -92% | -$243K |
|
|
BHVN
477
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $22K | ﹤0.01% |
163
| – | – |
|
478
Ulta Beauty
ULTA
$23.5B
| $21K | ﹤0.01% |
50
+48
| +2,400% | +$18.6K |
|
479
Arthur J. Gallagher & Co
AJG
$64.5B
| $20K | ﹤0.01% |
118
+100
| +556% | +$16.3K |
|
480
ASML
ASML
$673B
| $20K | ﹤0.01% |
25
-2
| -7% | -$1.59K |
|
|
BPMC
481
DELISTED
Blueprint Medicines
BPMC
| $20K | ﹤0.01% |
188
| – | – |
|
482
PENN Entertainment
PENN
$2.56B
| $20K | ﹤0.01% |
392
| – | – |
|
|
BLDP
483
Ballard Power Systems
BLDP
$766M
| $19K | ﹤0.01% |
1,500
| – | – |
|
484
Progyny
PGNY
$2.21B
| $19K | ﹤0.01% |
372
-9
| -2% | -$504 |
|
485
Rio Tinto
RIO
$166B
| $19K | ﹤0.01% |
289
+5
| +2% | +$324 |
|
486
Sanofi
SNY
$104B
| $19K | ﹤0.01% |
372
+5
| +1% | +$247 |
|
487
Toast
TOST
$20.5B
| $19K | ﹤0.01% |
+560
| New | +$25.9K |
|
488
Varex Imaging
VREX
$778M
| $19K | ﹤0.01% |
592
-39
| -6% | -$1.11K |
|
489
Scotiabank
BNS
$108B
| $18K | ﹤0.01% |
257
-7
| -3% | -$463 |
|
490
Cricut
CRCT
$1.26B
| $18K | ﹤0.01% |
809
| – | – |
|
491
Graco
GGG
$13.5B
| $18K | ﹤0.01% |
226
+6
| +3% | +$456 |
|
492
PJT Partners
PJT
$4.3B
| $18K | ﹤0.01% |
240
-43
| -15% | -$3.43K |
|
493
Solid Biosciences
SLDB
$903M
| $18K | ﹤0.01% |
667
| – | – |
|
494
TaskUs
TASK
$652M
| $18K | ﹤0.01% |
331
| – | – |
|
495
Tractor Supply
TSCO
$18B
| $18K | ﹤0.01% |
375
-3,425
| -90% | -$150K |
|
496
Vanguard Extended Market ETF
VXF
$31.8B
| $18K | ﹤0.01% |
101
+22
| +28% | +$4.14K |
|
497
Arrowhead Research
ARWR
$12.5B
| $17K | ﹤0.01% |
254
| – | – |
|
498
Consolidated Edison
ED
$39.3B
| $17K | ﹤0.01% |
198
-48
| -20% | -$3.77K |
|
499
Eversource Energy
ES
$26.7B
| $17K | ﹤0.01% |
187
-1
| -0.5% | -$86 |
|
500
Factset
FDS
$10.1B
| $17K | ﹤0.01% |
34
+30
| +750% | +$13.5K |
|
Similar funds
CGIC
AAM
CL
CPA
GUB
SCM
KLI
WC
Manchester Capital Management's Q4 2021 Portfolio in Review
As of Q4 2021, Manchester Capital Management held 1,145 positions worth $764M, up 4.6% from $731M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Manchester Capital Management withdrew a net $43M in Q4 2021, closing 119 positions and reducing 260 holdings. Its most notable exit was Amedisys, an estimated $2.85M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 19% a quarter earlier, followed by Technology and Financials.
Against the trend, Manchester Capital Management opened a new position in Vanguard Health Care ETF worth $24.8M.
- Manchester Capital Management's largest Q4 2021 buy was Vanguard Health Care ETF: 93,181 shares worth $24.8M.
- Manchester Capital Management added most to Vanguard Short-Term Corporate Bond ETF in Q4 2021, an estimated $10.2M increase.
- Manchester Capital Management's biggest Q4 2021 reduction was Apple, cutting an estimated $35.3M.
- Manchester Capital Management fully exited Amedisys in Q4 2021, selling an estimated $2.85M.
- Manchester Capital Management's ten largest holdings make up 54% of its $764M portfolio in Q4 2021.
- Manchester Capital Management opened 99 new positions and closed 119 in Q4 2021.
- Manchester Capital Management's portfolio value rose 4.6% quarter-over-quarter to $764M.
Based on Manchester Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.